Predictive factor

What it is

A predictive factor is a characteristic that indicates how well a glioma is likely to respond to a specific treatment — as opposed to a prognostic factor, which indicates the likely outcome overall. A key example is MGMT methylation status, which predicts response to the chemotherapy drug temozolomide.

Understanding Predictive factor

While prognostic factors tell you about likely outcome in general, predictive factors tell you whether a particular treatment is likely to work — information that directly helps choose therapy. The clearest glioma example is MGMT promoter methylation: methylated tumors respond better to temozolomide, so MGMT status helps decide how to use that drug (especially in older patients). Other examples of treatment-guiding features include the presence of an actionable mutation (such as BRAF V600E, predicting response to BRAF-targeted therapy, or an IDH mutation, indicating eligibility for IDH inhibitors) and 1p/19q codeletion (oligodendrogliomas being especially chemo-responsive). Predictive factors are central to personalized treatment, matching therapies to the tumors most likely to benefit. Some features are both prognostic and predictive (MGMT methylation is an example). Identifying predictive factors relies on molecular testing. Understanding predictive factors in gliomas clarifies features that guide treatment choices by indicating likely response.

Why it matters

Understanding predictive factors helps patients and families see how certain tumor features guide treatment choices — indicating which therapies are likely to work, such as MGMT status for temozolomide — enabling more personalized care.